Evidence map›Paper›PMID 41662431›Full record

ArticlePLoS pathogens2026

Breaking disulfide bonds in a weakly bactericidal α-defensin unleashes a potent antimicrobial peptide with an altered conformation.

Gan Luo, Mingzhu Zhao, Qingxia Wang, Yang Zhou, Dan Yao, Jue Zhang, Gang Wang, Junjie Zhang, Chongbing Liao, Wuyuan Lu

Abstract read
In one paragraph

Article in PLoS pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Gan LuoShanghai Institute of Infectious Disease and Biosecurity, Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Science, Fudan University, Shanghai, China.
Mingzhu ZhaoShanghai Institute of Infectious Disease and Biosecurity, Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Science, Fudan University, Shanghai, China.
Qingxia WangShanghai Institute of Infectious Disease and Biosecurity, Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Science, Fudan University, Shanghai, China.
Yang ZhouShanghai Institute of Infectious Disease and Biosecurity, Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Science, Fudan University, Shanghai, China.
Dan YaoShanghai Institute of Infectious Disease and Biosecurity, Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Science, Fudan University, Shanghai, China.
Jue ZhangShanghai Institute of Infectious Disease and Biosecurity, Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Science, Fudan University, Shanghai, China.
Gang WangShanghai Institute of Infectious Disease and Biosecurity, Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Science, Fudan University, Shanghai, China.
Junjie ZhangShanghai Institute of Infectious Disease and Biosecurity, Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Science, Fudan University, Shanghai, China.
Chongbing LiaoShanghai Institute of Infectious Disease and Biosecurity, Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Science, Fudan University, Shanghai, China.
Wuyuan LuShanghai Institute of Infectious Disease and Biosecurity, Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Science, Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0003-1318-9968

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Harnessing antimicrobial peptides as bactericidal agents affords an attractive approach to developing new anti-infective therapies. We found that abolishing disulfide bonding in mouse cryptdin 1 (Crp1), a weakly bactericidal α-defensin of 35 residues, turned it into a potent antimicrobial peptide against Gram-negative bacteria. Here we report that Crp1 in its natively folded β-sheet structure forms high-ordered nanonets to cloak, but not kill, Escherichia coli, whereas its disulfide-devoid linear counterpart (L-Crp1) readily disintegrates the bacterial membrane as monomers. L-Crp1 adopts a helix-loop-helix conformation in molecular dynamics simulations, likely conducive to productive peptide-membrane interactions detrimental to bacteria. A truncated peptide spanning the helix-loop-helix, L-Crp11-25, maintains the same conformation as and similar membranolytic and bactericidal activities to L-Crp1. Remarkably, intraperitoneally administered L-Crp11-25 rescues E. coli-challenged mice from lethality in a sepsis model by effectively reducing bacterial burden, inflammation and tissue damage. Our studies cultivate additional mechanistic insights into the mode of action of defensins and shed new light on how to harness these host factors for potential therapeutic use.

Indexed as

alpha-DefensinsAntimicrobial PeptidesDisulfidesEscherichia coli InfectionsSepsisAnimalsEscherichia coliMiceProtein Conformationalpha-DefensinsAntimicrobial PeptidesDisulfides

Identifiers

PMID41662431
PMCPMC12904582

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.